Intravenous ω-3 Fatty Acids Plus Gemcitabine

Area of Science:

• Oncology
• Clinical Pharmacology
• Nutritional Science

Background:

• Marine-derived omega-3 fatty acids (ω-3FAs) demonstrate antitumor properties and enhance quality of life (QOL) in cancer patients.
• Potential mechanisms include the reduction of proangiogenic and proinflammatory factors.
• This study explores intravenous ω-3FAs as an adjunct to gemcitabine therapy for advanced pancreatic cancer.

Purpose of the Study:

• To evaluate the efficacy of intravenous ω-3FAs in augmenting gemcitabine's antitumor activity in advanced pancreatic cancer.
• To assess the impact of this combination therapy on patients' quality of life (QOL).

Main Methods:

• Fifty patients with advanced pancreatic cancer received weekly gemcitabine (1000 mg/m³).
• Intravenous ω-3 rich lipid emulsion (100 g) was administered for 3 weeks, followed by a 1-week rest, continuing for up to 6 cycles.
• Primary endpoint was objective response rate; secondary endpoints included survival, QOL, and adverse events.

Main Results:

• Objective response rate was 14.3%, with a disease control rate of 85.7%.
• Median overall survival was 5.9 months, and progression-free survival was 4.8 months.
• Significant improvements in QOL scores were observed in over 47% of patients, with notable increases in global health and symptom-specific domains.

Conclusions:

• Intravenous ω-3FAs combined with gemcitabine demonstrate enhanced antitumor activity and QOL benefits in advanced pancreatic cancer.
• The combination therapy shows promise and warrants further investigation in a randomized phase III trial.